MELPHALAN in Slovenian translation

• melfalan
• melfalanom

Examples of using Melphalan in English and their translations into Slovenian

Cases of AML have been observed in clinical trials of newly diagnosed multiple myeloma in patients taking lenalidomide treatment in combination with melphalan or immediately following high dose melphalan and ASCT(see section 4.4).
V kliničnih preskušanjih novo diagnosticiranega diseminiranega plazmocitoma so pri bolnikih, ki so se zdravili z lenalidomidom v kombinaciji z melfalanom ali takoj po velikem odmerku melfalana in ASCT, opazili primere AML(glejte poglavje 4.4).

These include the anti-tumour agent melphalan, medicines to render you unconscious during ILP,
To so protitumorsko zdravilo melfalan, zdravila, zaradi katerih se posega ne boste zavedali,

Melphalan is given during the same operation over 60 minutes,
Med istim postopkom, 30 minut po začetku perfuzije z zdravilom Beromun, se doda melfalan v trajanju 60 minut, pri čemer je treba temperaturo povečati

bortezomib(70%) melphalan(65%), thalidomide(48%), and lenalidomide(6%).
bortezomib(70%), melfalan(65%), talidomid(48%) in lenalidomid(6%).

together with the anti- tumour agent melphalan, for the treatment of soft tissue sarcoma of the arms and legs.
hkrati s protitumorsko učinkovino melfalan, za zdravljenje sarkoma v mehkem tkivu roke ali noge.

Table 4: Comparison of haematological disorders for the melphalan, prednisone(MP) and melphalan, prednisone, thalidomide(MPT)
Preglednica 4: Primerjava hematoloških bolezni za kombinacijo melfalana, prednizona(MP) in kombinacijo melfalana, prednizona in talidomida(MPT)

To stop the blood containing a high dose of BEROMUN and melphalan from flowing into the rest of your body,
Da bi preprečili odtekanje krvi, ki vsebuje velik odmerek BEROMUNA in melfalana v druge dele telesa,

Immediately after the administration of BEROMUN and melphalan, after you have regained consciousness from the isolated limb perfusion(ILP),
Takoj po dajanju BEROMUNA in melfalana, ko boste po izolirani perfuziji okončine spet pri zavesti,

Cycles of 50 mg/kg body weight(BW) cyclophosphamide(BuCy4) or one administration of 140 mg/m² melphalan(BuMel) initiated for at least 24 hours following the 16th dose of Busilvex.(see section 4.5).
Cikli po 50 mg/kg telesne mase(TM) ciklofosfamida(BuCy4) ali en odmerek 140 mg/m2 melfalana(BuMel), ki se začnejo vsaj 24 ur po 16. odmerku zdravila Busilvex(glejte poglavje 4.5).

ILP allows that tumour cells in your limb can be exposed to a very high dose of Beromun and melphalan, enhancing their anti-tumour effect, but without reaching the rest of the body,
Med postopkom izolirane perfuzije okončine so tomorske celice v okončini izpostavljene zelo velikima odmerkoma zdravila Beromun in melfalana, kar poveča njun protitumorski učinek,

The melphalan recommended starting dose is 0.1 to 0.2 mg/kg daily according to bone marrow reserve along with a further 50% dose reduction for moderate creatinine clearance.
Priporočeni začetni odmerek melfalana je 0,1 do 0,2 mg/kg na dan glede na rezervo kostnega mozga, odmerek se zmanjša še za nadaljnjih 50% pri zmerni očistek kreatinina.

with lenalidomide in combination with low dose dexamethasone(Rd and Rd18) than with melphalan, prednisone and thalidomide(MPT) were.
pri lenalidomidu v kombinaciji z deksametazonom v majhnem odmerku(Rd in Rd18) kot pri melfalanu, prednizonu in talidomidu(MPT), sta bila.

together with the anti-tumour agent melphalan.
hkrati s protitumorskim zdravilom melfalanom.

immediately following high dose melphalan and autologous stem cell transplantation.
takoj po visokem odmerku melfalana in avtologni presaditvi matičnih celic.

Busilvex is administered as a two-hour infusion every 6 hours over 4 consecutive days for a total of 16 doses prior to cyclophosphamide or melphalan and haematopoietic progenitor cell transplantation(HPCT).
Busilvex se uporablja v obliki dveurne infuzije vsakih 6 ur 4 zaporedne dni, kar je skupaj 16 odmerkov pred uporabo ciklofosfamida ali melfalana in transplantacijo hematopoetskih progenitorskih celic(HPCT).

The combination of lenalidomide with melphalan and prednisone in multiple myeloma patients is associated with a higher incidence of grade 3
Kombinacija lenalidomida z melfalanom in prednizonom pri bolnikih z diseminiranim plazmocitomom je povezana z večjo incidenco trombocitopenije 3.

The combination of lenalidomide with melphalan and prednisone in newly diagnosed multiple myeloma patients is associated with a higher incidence of grade 3
Kombinacija lenalidomida z melfalanom in prednizonom pri bolnikih z novo diagnosticiranim diseminiranim plazmocitomom je povezana z večjo incidenco trombocitopenije 3.

patients receiving melphalan and prednisone survived for an average of 33.2 months from the start of the study, compared with 51.6
so prejemali melfalan in prednizon so v povprečju preživeli še 33,2 meseca od začetka študije v primerjavi z 51,6 meseca pri zdravljenju,

The most commonly observed adverse reactions associated with the use of thalidomide in combination with melphalan and prednisone are:
Najbolj pogosto opaženi neželeni učinki, povezani z uporabo talidomida v kombinaciji z melfalanom in prednizonom, so:

The independent reviewers agreed that 62% of the patients receiving Beromun and melphalan(90 out of 145) had a better outcome than predicted, since their limb was saved without surgery
Neodvisni pregledovalci so se strinjali, da je imelo 62% bolnikov, ki so prejeli zdravilo Beromun in melfalan(90 bolnikov od 145), boljši izid od pričakovanega, saj je bila njihova okončina ohranjena,